The agreement gives a newly formed company backed by Population Health Partners and ARCH Venture Partners ex-China rights to Haisco’s Phase II-ready oral THR-β agonist for obesity and metabolic disorders.

The non-exclusive agreement gives SignalChem access to Monod Bio’s LuxSit luciferase and NovoBodies technologies for custom research assays and protein-fusion services, extending the commercial reach of its AI-designed protein platform.

The agreement gives Genentech ex-South Korea rights to a Phase I non-incretin UCN2 analogue designed to reduce weight while preserving lean body mass, adding a differentiated mechanism to Roche’s growing cardiometabolic pipeline.

The agreement expands Lupin's European ophthalmology portfolio by adding the first once-daily dual-agent eye drop approved for presbyopia while strengthening its specialty eye care strategy.

The exclusive agreement expands Mankind Pharma's injectable diabetes portfolio with two long-acting insulin analogues while strengthening its strategy of in-licensing innovative therapies for the Indian market.

The agreement adds a late-stage oral therapy for rare genetic photodermatoses to LEO Pharma's dermatology pipeline while expanding its focus on rare skin diseases.

The agreement gives Zydus subsidiary Sentynl Therapeutics an option for exclusive US commercial and global manufacturing rights to Mereo BioPharma’s oral neutrophil elastase inhibitor, with Mereo leading preparations for pivotal development.

The agreement gives Sentynl an exclusive pathway to commercialise the Phase III-ready rare lung disease therapy in the US while providing global manufacturing rights and funding support for late-stage development.

The partnership gives Sobi potential global commercial and development rights to the first-in-class anti-KIR3DL2 antibody while funding Innate’s Phase III programme in cutaneous T-cell lymphoma.

The rights reversion gives Actimed full control of the muscle-wasting candidate across all indications, with amyotrophic lateral sclerosis remaining its primary development focus.

The agreement gives an undisclosed global pharmaceutical company worldwide rights to use Alteogen’s ALT-B4 technology to develop and commercialise a subcutaneous formulation of an existing biologic.

Pathos AI licenses first-in-class bispecific ADC JSKN016 from Alphamab Oncology in deal worth up to $4.8 billion

The spin-out creates a dedicated US oncology company to raise capital and advance Lupin’s PRMT5 and SOS1 programmes through global clinical development.

The agreement expands AstraZeneca’s oncology portfolio with an oral EGFR inhibitor for non-small-cell lung cancer, as Dizal seeks to broaden Zegfrovy’s use into earlier lines of treatment.

The agreement gives AstraZeneca exclusive rights to develop, manufacture and commercialise TQC3721 outside China.